[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"juvenile-idiopathic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:juvenile-idiopathic-arthritis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,49,80,110,135,164,188,209,238,267,289,321,345,367,404,422,453,478,505,527,552,572,595,614,641],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100345151","phase-3-a-study-of-baricitinib-in-participants-from-1-year-to-less-than-18-years-old-with-juvenile-idiopathic-arthritis-100345151",false,"NCT03773965","A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis","A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to \u003C18 Years of Age With Juvenile Idiopathic Arthritis (JIA)","JUVE-X","Inclusion Criteria:\n\n* Participants must have completed a previous study of baricitinib for the treatment of JIA.\n\nExclusion Criteria:\n\n* Participants must not have had a permanent discontinuation of baricitinib in the prior study.\n* Participants must have not developed an allergy to baricitinib.","ALL","1 Year","18 Years",{"count":22,"type":23},190,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.",[29],"Juvenile Idiopathic Arthritis",[31,32,33,34,35],"Polyarticular JIA","Oligoarthritis","Juvenile psoriatic arthritis (JPsA)","Enthesitis-related juvenile idiopathic arthritis (ERA)","Systemic JIA with and without systemic features","RECRUITING","2026-06-19",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":42,"type":40},"2019-04-05",{"date":44,"type":23},"2031-07",{"name":46,"class":47},"Eli Lilly and Company","INDUSTRY",80,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100643056","sarcopenia-and-juvenile-idiopathic-arthritis-100643056","NCT07634354","Sarcopenia and Juvenile Idiopathic Arthritis","Prevalence Study of Sarcopenia in Juvenile Idiopathic Arthritis","SAJI","inclusion criteria :\n\n* Patients followed in French hospitals participating in the study for juvenile idiopathic arthritis, all forms combined, diagnosed according to the ILAR criteria defined in Edmonton in 2001\n* Patients aged 15 to 40 years\n* Affiliated to social security\n* Agreeing to participate in the study and having given their written consent (signed consent form).\n\nIn the case of a minor patient, the consent of the patient and their legal guardians is required.\n\nexclusion criteria :\n\n* Patient under legal guardianship\n* Patient not covered by social security\n* Pregnant woman\n* Inability to perform a functional test required by the study (grip test or whole-body DEXA scan)\n* Inability to understand the questionnaires","15 Years","40 Years",{"count":60,"type":23},200,[62],"NA","Juvenile idiopathic arthritis (JIA) is a rare chronic inflammatory rheumatic disease that begins during childhood and may persist into adulthood in many patients. In addition to joint pain, swelling, and long-term articular damage, chronic inflammatory diseases may also be associated with early sarcopenia, defined as a loss of muscle strength and muscle mass. While this association has been described in adult inflammatory rheumatic diseases, it has not been well studied in patients with JIA.\n\nThe aim of this study is to screen for sarcopenia in adolescents and adults with JIA in France. Sarcopenia will be assessed using validated questionnaires, hand grip strength measured with a Jamar dynamometer, and body composition measured by dual-energy X-ray absorptiometry (DEXA). Completion of validated questionnaires will assess nutritional status, fatigue, physical activity, and functional impact. Socio-demographic and clinical data will also be collected from medical records.\n\nThis multicenter cross-sectional study will be conducted between June 2026 and October 2027 in 11 French hospitals. Eligible participants are patients aged 15 to 40 years with JIA diagnosed according to ILAR criteria and followed in a French hospital.\n\nThis study will provide the first estimate of sarcopenia prevalence among patients with JIA in France. It will also help identify factors associated with sarcopenia and its impact on daily functioning and quality of life. In the longer term, the findings may help clinicians better identify patients at risk and support earlier management focused on disease control, physical activity, and nutritional care.",[29],[66,67],"Juvenile idiopathic arthritis","Sarcopenia","NOT_YET_RECRUITING","2026-06-03",{"date":71,"type":40},"2026-06-08",{"date":73,"type":23},"2026-06",{"date":75,"type":23},"2027-10",{"name":77,"class":78},"CHU de Reims","OTHER",1,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":18,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":79},"100582955","dynamic-gait-index-as-a-functional-gait-assessment-measure-in-children-with-jia-100582955","NCT06870045","Dynamic Gait Index as a Functional Gait Assessment Measure in Children With JIA","Investigation of Validity and Reliability of Dynamic Walking Index in Childhood Rheumatic Diseases","Inclusion Criteria:\n\n* Study Group;\n* Having a JIA diagnosis according to ILAR criteria between the ages of 8-16,\n* Having unilateral knee joint involvement that will affect walking\n* Being compatible, volunteer and cooperative in the study Control Group;\n\n  1. Not having any neurological or orthopedic diagnosis\n  2. Being between the ages of 8-16\n  3. Being at a mental level that can understand the commands of the person performing the evaluation\n\nExclusion Criteria:\n\n* Study Group;\n* Having an additional neurological or orthopedic diagnosis accompanying JIA and affecting treatment results,\n* Having lower extremity asymmetry or active lower extremity involvement other than the knee joint that will affect walking.\n\nControl Group;\n\n-Having any health problem that may affect the study",true,"8 Years","16 Years",{"count":91,"type":23},52,"OBSERVATIONAL","Juvenile idiopathic arthritis (JIA) is one of the most common chronic rheumatic diseases seen in childhood. Pain, joint swelling and loss of function caused by inflammation significantly reduce the patients' quality of life and lead to muscle weakness, limited range of motion and gait disorders. Although there are various clinical assessment methods, there is no functional test in the current literature that evaluates walking in children with JIA.\n\nThe Dynamic Gait Index (DGI) is a functional walking scale that evaluates walking on level ground, walking while changing speed, walking with sideways head turns, walking with vertical head turns, walking with pivot turns, walking by jumping over obstacles, going around obstacles and climbing stairs. While the DGA is widely used in the clinical assessment of walking in older adults and other pediatric patient groups, it has not yet been investigated for the assessment of walking difficulties in children with JIA. This study aimed to determine whether the DYI is a usable tool for assessing walking in children with JIA.",[29,95],"Childhood Rheumatic Disease",[97,98,99,100],"juvenile idiopathic arthritis","gait","dynamic gait index","childhood rheumatic diseases","2026-06-01",{"date":103,"type":40},"2026-06-02",{"date":105,"type":40},"2025-02-01",{"date":107,"type":23},"2026-10",{"name":109,"class":78},"Istanbul University - Cerrahpasa",{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":117,"maxAge":20,"enrollmentInfo":118,"targetDuration":120,"studyType":92,"phases":4,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100640752","validity-and-reliability-of-the-international-physical-fitness-questionnaire-and-the-self-perceived-health-related-physical-fitness-questionnaire-in-children-and-adolescents-with-jia-and-fmf-100640752","NCT07617558","Validity and Reliability of the International Physical Fitness Questionnaire and the Self-Perceived Health-Related Physical Fitness Questionnaire in Children and Adolescents With JIA and FMF","Investigation of the Validity and Reliability of the International Physical Fitness Questionnaire and the Self-Perceived Health-Related Physical Fitness Questionnaire for Children in Children and Adolescents Diagnosed With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever","Inclusion Criteria:\n\n* Age between 10 and 18 years\n* Diagnosis of Familial Mediterranean Fever (FMF) or Juvenile Idiopathic Arthritis (JIA) established by a pediatric rheumatologist at least six months prior\n* Voluntary willingness to participate in the study\n* Provision of informed consent by both the participant and their parents\u002Fguardians\n* Ability to ambulate independently, communicate effectively, and comply with the instructions required for the research assessments\n* Sufficient literacy to comprehend written instructions and complete study-related materials\n\nExclusion Criteria:\n\n* Having a history of a mental or psychological problem that would prevent the understanding of questions or compliance with given instructions.\n* Medically unstable conditions (history of hospitalization due to heart or lung disease or a disease flare within the 4 weeks prior to the test).\n* Having a history of a chronic disease of cardiovascular, orthopedic, neuromuscular, or neurological origin that could affect physical fitness.\n* Having a history of trauma affecting the musculoskeletal system within the last 6 months.","10 Years",{"count":119,"type":23},100,"7 Days","Juvenile Idiopathic Arthritis (JIA) and Familial Mediterranean Fever (FMF), two of the most prevalent pediatric rheumatologic diseases, significantly compromise the physical health of children and adolescents, leading to reduced physical fitness, muscle weakness, and a sedentary lifestyle. This study aims to evaluate the validity and reliability of the International Fitness Scale (IFS) and the Self-Perceived Health-Related Fitness Questionnaire for Children (PHFQ-C) as assessment tools for physical fitness in individuals diagnosed with JIA and FMF. Our hypothesis is that these scales will provide demonstrably reliable and valid data within this patient population. To test this, 98 patients aged 10-18 years, recruited from the Pediatric Rheumatology Clinic at Istanbul Faculty of Medicine, will participate. Their physical fitness will be objectively measured using the FitnessGram Test Battery (assessing aerobic capacity, muscular strength, and flexibility), while the IFS and PHFQ-C will be administered online. Statistical analysis, conducted using SPSS 25.0, will employ Pearson\u002FSpearman correlation for validity and Cronbach's alpha and test-retest Intraclass Correlation Coefficient (ICC) for reliability.\n\nThe expected findings will confirm the utility of the IFS and PHFQ-C as practical, economical, and valid instruments for assessing physical fitness in children and adolescents with JIA\u002FFMF. Promoting the widespread use of these scales in clinical settings will facilitate the rapid and convenient evaluation of patients' fitness levels, thereby enabling the development of early, targeted intervention strategies and ultimately contributing to an improved quality of life. Furthermore, by offering a validated alternative to standard test batteries-which are often cumbersome due to requirements for time, specialized equipment, and expert personnel-this work will make a valuable methodological contribution to the existing scientific literature.",[29,123],"Familial Mediterranean Fever",[29,123,125,126,127],"physical fitness","reliability","validity","2026-05-29",{"date":101,"type":40},{"date":131,"type":23},"2026-07-01",{"date":133,"type":23},"2026-10-30",{"name":109,"class":78},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":24,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100486096","phase-3-study-of-oral-upadacitinib-and-subcutaneousintravenous-tocilizumab-to-evaluate-change-in-disease-activity-adverse-events-and-how-drug-moves-through-the-body-of-pediatric-and-adolescent-participants-with-active-systemic-juvenile-idiopathic-arthritis-100486096","NCT05609630","Study of Oral Upadacitinib and Subcutaneous\u002FIntravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.","A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis","SELECT-sJIA","Inclusion Criteria:\n\n\\- Baseline with a total body weight of 10 kg or higher at screening and symptoms of systemic juvenile idiopathic arthritis (sJIA) according to International League of Associations for Rheumatology (ILAR) criteria for at least 6 weeks prior to Screening, with onset prior to 16 years old, and meet the following conditions:\n\n* Must have active sJIA with at least 2 active joints at Screening and Baseline, fever more than 38°C on at least one day within 14 consecutive days before the Screening Visit, and an erythrocyte sedimentation rate (ESR) or high-sensitivity C-reactive protein (hsCRP) \\> upper limit of normal (ULN) at Screening. OR At least 4 active joints at Screening and Baseline and an ESR or hsCRP \\> ULN at Screening.\n* Must have inadequate response to previous treatment with nonsteroidal anti-inflammatory drugs and\u002For systemic glucocorticoids, as judged by the investigator.\n* For Cohort 1, participants must not have had previous treatment with any IL-6 inhibitor. For Cohort 2, participants must have an intolerance or inadequate response to an IL-6 inhibitor as judged by the investigator.\n\nNote: For Cohort 1, participants must be ages 2 to \\\u003C 18 years old in countries where SC tocilizumab is not approved for sJIA.\n\nExclusion Criteria:\n\n* Has any type of juvenile idiopathic arthritis (JIA), other than sJIA, as defined by the ILAR criteria, and must not have a history or presence of any other autoimmune inflammatory condition other than sJIA.\n* Has uncontrolled severe systemic disease and\u002For impeding or active macrophage activation syndrome within 1 month prior to Baseline.","17 Years",{"count":145,"type":23},90,[26],"Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term \"idiopathic\" means \"of unknown origin\". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic\" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to \\\u003C 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed.\n\nUpadacitinib is an investigational drug being developed for the treatment of sJIA. Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive upadacitinib or tocilizumab reference. In cohort 2, participants will receive upadacitinib. Approximately 90 participants with sJIA will be enrolled in approximately 45 sites worldwide.\n\nParticipants will receive upadacitinib oral tablets once daily or oral solution twice daily or tocilizumab subcutaneous injection or intravenous infusion as per local label for 52 weeks and followed for approximately 30 days.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits\u002Fcalls during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.",[29],[150,151,152,153],"Systemic Juvenile Idiopathic Arthritis","sJIA","Upadacitinib","ABT-494","2026-05-21",{"date":156,"type":40},"2026-05-26",{"date":158,"type":40},"2023-10-02",{"date":160,"type":23},"2029-06",{"name":162,"class":47},"AbbVie",56,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":143,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100285118","phase-2-a-repeated-dose-finding-study-of-sarilumab-in-children-and-adolescents-with-systemic-juvenile-idiopathic-arthritis-skyps-100285118","NCT02991469","A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)","An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase","SKYPS","Inclusion criteria :\n\n* Male and female patients aged ≥1 and ≤17 years (or country specified age requirement, ≥6 to ≤17 years for Russia) at the time of the screening visit.\n* Diagnosis of systemic JIA subtype according to the International Associations against Rheumatism (ILAR) 2001 Juvenile Idiopathic Arthritis (JIA) Classification Criteria OR According to 2024 EULAR\u002FPReS recommendation at Screening.\n* Patient with an inadequate response to current treatment and considered as a candidate for a biologic disease modifying anti rheumatic drug (DMARD) as per investigator's judgment.\n\nExclusion criteria:\n\n* Body weight \\\u003C10 kg or \\>60 kg for patients enrolled in the ascending dose cohorts, then body weight \\\u003C10 kg for patients subsequently enrolled at the selected dose.\n* Uncontrolled severe systemic symptoms and\u002For Macrophage Activation Syndrome (MAS) within 6 months prior to screening.\n* History of or ongoing interstitial lung disease, pulmonary hypertension, pulmonary alveolar proteinosis.\n* If nonsteroidal anti-inflammatory drugs (NSAIDs) (including cyclo oxygenase-2 inhibitors \\[COX-2\\]) taken, dose stable for less than 2 weeks prior to the baseline visit and\u002For dosing prescribed outside of approved label.\n* If non-biologic DMARD taken, dose stable for less than 6 weeks prior to the baseline visit or at a dose exceeding the recommended dose as per local labeling.\n* If oral glucocorticoid taken, dose exceeding equivalent prednisone dose 1 mg\u002Fkg\u002Fday (or 60 mg\u002Fday) within 3 days prior to baseline.\n* Use of parenteral or intra-articular glucocorticoid injection within 4 weeks prior to baseline.\n* Prior treatment with anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.\n* Treatment with any biologic treatment for sJIA within 5 half-lives prior to the first dose of sarilumab (the required off treatment periods and procedures may vary according to local requirements).\n* Treatment with a Janus kinase inhibitor within 4 weeks prior to the first dose of sarilumab; and treatment with growth hormone within 4 weeks prior to the first dose of sarilumab (the required off treatment periods and procedures may vary according to local requirements).\n* Treatment with any investigational biologic or non-biologic product within 8 weeks or 5 half-lives prior to baseline, whichever is longer.\n* Exclusion related to tuberculosis.\n* Exclusion criteria related to past or current infection other than tuberculosis.\n* Any live, attenuated vaccine within 4 weeks prior to the baseline visit, such as varicella-zoster, oral polio, rubella vaccines. Killed or inactive vaccine may be permitted based on the Investigator's judgment.\n* Exclusion related to history of a systemic hypersensitivity reaction to any biologic drug and known hypersensitivity to any constituent of the product.\n* Laboratory abnormalities at the screening visit (identified by the central laboratory).\n* Severe cardiac disease due to sJIA.\n* Pregnant or breast-feeding female adolescent patients.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",{"count":173,"type":23},51,[175],"PHASE2","Primary Objective:\n\nTo describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population.\n\nSecondary Objective:\n\nTo describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety of sarilumab in patients with sJIA.",[29],"2026-05-20",{"date":180,"type":40},"2026-05-22",{"date":182,"type":40},"2018-08-09",{"date":184,"type":23},"2031-01-17",{"name":186,"class":47},"Sanofi",32,{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":20,"enrollmentInfo":195,"targetDuration":4,"studyType":24,"phases":197,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":196},"100533147","phase-1-study-to-measure-filgotinib-in-the-blood-of-children-and-teenagers-with-arthritis-taking-filgotinib-scalesia-100533147","NCT06222034","Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)","An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis","Key Inclusion Criteria:\n\n* Participant with a body mass index (BMI) within the 5th to 95th percentiles for the age and gender (based on World Health Organization BMI charts). Participant must have a minimum weight of 15 kg.\n* Participant must meet the International League of Associations for Rheumatology classification for 1 of the following categories and have, according to the investigator's judgment, moderately to severely active disease that is not adequately controlled with his\u002Fher current therapy.\n\n  * Rheumatoid factor (RF)-positive polyarthritis\n  * RF-negative polyarthritis\n  * Oligoarthritis\n  * Psoriatic arthritis\n  * Enthesis-related arthritis (ERA) Note: Historical Human leukocyte antigen B-27 (HLA-B27) results are considered appropriate for ERA diagnosis during screening.\n  * Systemic JIA with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment\n* Participant with intolerance or a history of inadequate response to at least one of the following medications for the treatment of JIA, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs and biological disease-modifying antirheumatic drugs (including methotrexate) and non-steroidal anti-inflammatory drugs for ERA and psoriatic arthritis.\n* Female participants of childbearing potential (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test.\n\nKey Exclusion Criteria:\n\n* Participant with persistent oligoarthritis.\n* Participant with undifferentiated arthritis.\n* Participant with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis).\n* Active infection that is clinically significant, as per judgment of the investigator.\n* Participant with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement).\n* Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria).\n\nNote: Other protocol defined Inclusion\u002F Exclusion criteria may apply.",{"count":196,"type":23},10,[198],"PHASE1","A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).",[29],"2026-05-19",{"date":180,"type":40},{"date":204,"type":40},"2024-05-13",{"date":206,"type":23},"2026-08",{"name":208,"class":47},"Alfasigma S.p.A.",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":20,"enrollmentInfo":217,"targetDuration":4,"studyType":24,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100552550","feasibility-of-a-diet-intervention-for-juvenile-arthritis-100552550","NCT06474546","Feasibility of a Diet Intervention for Juvenile Arthritis","The Role of Diet, as Mediated by the Gut Microbiome, on Childhood Arthritis Disease Activity: a Feasibility Intervention Study","DIGEST-JA","Inclusion Criteria:\n\n* Ages 8-18 years\n* Diagnosis of JIA (excluding systemic JIA, enthesitis-related arthritis, and rheumatoid factor (RF) positive polyarthritis) as per International League of Associations for Rheumatology (ILAR) criteria. (For this feasibility study, there will be no requirement for any particular level of disease activity.)\n* Subjects on stable treatment - i.e., any medical treatment with disease-modifying antirheumatic drugs (DMARDs) and\u002For systemic or intraarticular corticosteroids, has been unchanged for 8 weeks, and is unlikely to change for 12 weeks as judged by the treating physician.\n* Willingness to provide stool samples.\n* English or French fluency adequate to answer the study questionnaires, and participate in diet instruction, as judged by the enrolling physician.\n\nExclusion Criteria:\n\n* Documented specific food allergies, celiac disease.\n* Co-morbidities that might impact the tolerability of the study diet, e.g., type I diabetes, peptic ulcer disease, etc.",{"count":218,"type":23},54,[62],"Families of children with arthritis are highly interested in the benefits of diet to improve their child's disease and future health outcomes. Previous research shows that the germs - bacteria and other organisms - that live in the intestines (gut microbiome) are important to how well immune systems work, and that what people eat changes their gut microbiome. The investigators want to study whether a certain diet - based on the principles of the Mediterranean Diet - will improve arthritis for children and whether it was changes in the microbiome that led to improvement.\n\nFifty-four participants in this study will change their diet for an 8-week period, and will have the option of remaining on the diet for an additional 4 weeks. At three time points during the study (beginning, 8 weeks, and 12 weeks), participants will provide stool and blood samples, will complete questionnaires about diet and other aspects of lifestyle and health, and will complete a disease assessment by a clinician. From collecting all these samples and information, the investigators will be able to determine if the diet was successful in improving disease activity in children with arthritis and if the gut microbiome was changed as well.\n\nThis study will help the investigators figure out if a larger, and more definitive, study like this is possible to do in children with arthritis and will help the investigators design a bigger multinational study to confirm how diet affects disease outcomes and the microbiome in children with arthritis. If successful, this research will provide scientific knowledge to help families make their way through this difficult to- navigate topic.",[222,223,29],"Arthritis, Juvenile","Arthritis, Childhood",[225,226,227],"arthritis","diet","microbiome","2026-04-29",{"date":230,"type":40},"2026-05-05",{"date":232,"type":40},"2025-04-07",{"date":234,"type":23},"2028-10",{"name":236,"class":78},"The Hospital for Sick Children",7,{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":89,"enrollmentInfo":245,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":247,"conditions":248,"keywords":252,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":4},"100635532","tenosynovitis-in-polyarticular-and-oligoarticular-juvenile-idiopathic-arthritis-100635532","NCT07553910","Tenosynovitis in Polyarticular and Oligoarticular Juvenile Idiopathic Arthritis","Tenosynovitis in Juvenile Idiopathic Arthritis: Insights From Polyarticular and Oligoarticular Subtypes","Inclusion Criteria:\n\n* Children and adolescents (typically under 16 years of age at the time of onset) diagnosed with Juvenile Idiopathic Arthritis (JIA).\n* Patients of both genders.\n* Patients or their legal guardians who provide written informed consent\u002Fassent to participate in the study.\n\nExclusion Criteria:\n\n* Patients more than 16 years of age.\n* Patients with arthritis secondary to other known causes (e.g., trauma, infectious arthritis, malignancy, or other systemic autoimmune diseases like Systemic Lupus Erythematosus).\n* Patients with a history of major orthopedic surgery at the examined entheseal sites.\n* Active infection or metabolic disease that may affect musculoskeletal structures.\n* Patients who decline participation or fail to provide informed consent.",{"count":246,"type":23},106,"Juvenile Idiopathic Arthritis (JIA) is a chronic condition that causes joint inflammation in children. In some cases, the inflammation also affects the protective sheath surrounding the tendons, a condition known as tenosynovitis. Because tenosynovitis can be difficult to distinguish from regular joint swelling during a standard physical exam, specialized imaging tools like ultrasound are highly useful for an accurate diagnosis.\n\nThis observational study aims to determine how frequently tenosynovitis occurs in children and adolescents diagnosed with two specific subtypes of the disease: polyarticular and oligoarticular JIA.\n\nResearchers will evaluate participants up to 16 years of age receiving care at Assiut University Children Hospital. During the study, patients will undergo a standard clinical assessment, which includes a medical history review and a thorough physical examination of their joints and tendons. Routine laboratory blood tests will also be reviewed. To precisely detect any hidden tendon inflammation, doctors will perform a musculoskeletal ultrasound, which is a safe, radiation-free imaging procedure, on major tendon and joint sites. By comparing the clinical exams with the ultrasound findings, researchers hope to improve the early recognition and management of tendon inflammation in pediatric JIA patients.",[29,249,250,251],"Tenosynovitis","Polyarticular Juvenile Idiopathic Arthritis","Oligoarticular Juvenile Idiopathic Arthritis",[253,254,255,256,257],"Musculoskeletal Ultrasound","JIA","Pediatric Rheumatology","Enthesitis","Joint Inflammation","2026-04-21",{"date":260,"type":40},"2026-04-28",{"date":262,"type":23},"2026-05",{"date":264,"type":23},"2027-06",{"name":266,"class":78},"Assiut University",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":79},"100426473","development-of-a-therapeutic-endpoint-in-pediatric-rheumatologic-conditions-100426473","NCT04833465","Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions","Inclusion Criteria:\n\nIn order to be eligible for inclusion in the study, an individual must meet all of the following criteria:\n\n* Male or female ≥ 5 years of age at screening.\n* Documentation of a JIA, SLE or FM diagnosis as evidenced by history\n\nExclusion Criteria:\n\nAny individual who meets any of the following criteria will be excluded from participation in this study:\n\n• Documented history of eye disease precluding pupillometry","5 Years","21 Years",{"count":145,"type":23},"The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain and treatment in these populations and enable a much more precise approach to treatment. Such an endpoint stands to significantly improve outcomes in these patients by eliminating the need for a trial-and-error approach to treatment. This is a single site observational study that aims to collect initial pilot data in three distinct patient groups. As this is observational, there is no randomization or blinding in the study. Patients will be followed for a period of one year after enrollment. Baseline measurements will be taken at the time of enrollment, and at each subsequent standard of care clinic visit as feasible, for a period of one year. As this is an observational study, there will be no change to the treatment for any patient due to research activities. The primary objective of this study is the characterization of the nociceptive index in three pediatric rheumatology populations. The secondary objective is the characterization of the nociceptive index in these populations in response to standard of care interventions. This is necessary to demonstrate the ability of this approach to serve as an endpoint of treatment effect.",[29,278,279],"Systemic Lupus Erythematosus","Fibromyalgia","2026-04-03",{"date":282,"type":40},"2026-04-06",{"date":284,"type":40},"2021-07-16",{"date":286,"type":23},"2027-04",{"name":288,"class":78},"Children's National Research Institute",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":296,"maxAge":143,"enrollmentInfo":297,"targetDuration":4,"studyType":24,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":320},"100632737","phase-2-pharmacokinetics-efficacy-and-safety-of-olokizumab-in-patients-with-juvenile-idiopathic-arthritis-100632737","NCT07517575","Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis","An Open-label, Multicenter Study of the Pharmacokinetics, Efficacy and Safety of Olokizumab in Pediatric and Adolescent Patients With Active Juvenile Idiopathic Arthritis","Inclusion Criteria:\n\n1. Study informed consent form voluntarily and independently signed by patient legal representative\n2. Study assent form voluntarily and independently signed by minor study subject (patient)\n3. Male or female patients aged ≥12 and \\\u003C18 years (cohort 1 - subgroup A) or \\>2 and \\\u003C12 years (cohort 1 - subgroup B) or \\>2 and \\\u003C18 years (cohort 2) at the time of screening initiation and on Day 0\n4. Body weight at the start of screening and on Day 0 ≥45 kg (cohort 1 - subgroup A) or ≥30 and \\\u003C45 kg (cohort 1 - subgroup B) or ≥18 and \\\u003C30 kg (cohort 2)\n5. A reliable diagnosis of juvenile idiopathic arthritis (JIA) according to the JIA International League of Associations for Rheumatology (ILAR) 1 criteria with onset before the age of 16 years:\n\n   1. Seropositive or seronegative polyarthritis (pJIA) ≥3 months before screening, or\n   2. Systemic JIA (sJIA) for ≥3 months before screening, provided that joint symptoms persist without active systemic manifestations for ≥3 months before screening, or\n   3. Extended oligoarticular JIA (оJIA) ≥3 months before screening\n6. American College of Radiology (ACR) criteria of active polyarthritis are met: 5 or more active joints at screening and on Day 0\n7. C-reactive protein (CRP) level on screening or in anamnesis, not associated with alternative causes of increase other than the activity of the underlying disease, ≥6 mg\u002Fl\n8. Intolerance or failure of methotrexate in the dose of ≥15 mg\u002Fm\\^2\u002Fweek (or less, in a case of documented intolerance of higher doses) for ≥3 months in medical history\n\nExclusion Criteria:\n\n1. Prior use of any drug that acts directly on IL-6 or IL-6R\n2. If methotrexate is administered - any change in dose or in a formulation within 6 weeks prior to Day 0\n3. Previous therapy with marketed or experimental conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic disease-modifying anti-rheumatic drugs (bDMARDs) within less than 5 elimination half-lives\n4. Use of oral steroids in the doses above 0.2 mg\u002Fkg or 10 mg\u002Fday of prednisolone daily, whatever is lower, or a change in dose within 2 weeks prior to Day 0, or use of parenteral or topical steroids within 4 weeks prior to Day 0\n5. Change in dose of a non-steroidal anti-inflammatory drug (NSAID) within ≤2 weeks prior to Day 0\n6. Vaccination with live vaccines within 6 weeks before baseline, or planned vaccination with live vaccines during the study and\u002For within 6 weeks after the last olokizumab administration\n7. Active uveitis at screening or uveitis exacerbation within 24 weeks before screening\n8. Laboratory abnormalities (creatinine ≥1 mg\u002FdL (88 mM) for children aged 12 or ≥1.2 mg\u002FdL (106 mM) for children aged 13 and older; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5 х upper limit normal (ULN); platelets \\\u003C180,000\u002Fmm\\^3; white blood count (WBC) \\\u003C4000\u002Fmm\\^3; neutrophils \\\u003C2000\u002Fmm\\^3; hemoglobin ≤80 g\u002FL\n9. Exclusion criteria related to past or current infection other than tuberculosis\n10. Suspected or confirmed current tuberculosis (TB) infection, history of an active or latent TB infection\n11. Active course of a disease associated with formation of intestinal diverticula, or any other symptomatic gastrointestinal disease that may increase risk of perforation; or a history of diverticulitis or perforation; or concurrent Crohn's disease or ulcerative colitis\n12. Concurrent heart failure New York Heart Association (NYHA) III or IV functional class\n13. In patients with diabetes mellitus - HbA1c \\> 7% within the last 3 months (non-controlled diabetes mellitus)\n14. Patients with Steinbrocker class IV functional impairment\n15. Presence of systemic autoimmune or autoinflammatory disease, except JIA, or chronic autoimmune hepatitis or diseases of the primary immunodeficiencies group\n16. Patients with history of macrophage activation syndrome episodes\n17. Exclusion criteria related to concurrent diseases and conditions that may increase potential risk related to participation in the study and study drug exposure\n18. Known hypersensitivity to any component of the study drug\n19. Pregnant or breast-feeding female participants or planned pregnancy\n20. Other protocol-defined non-inclusion criteria apply","2 Years",{"count":298,"type":23},71,[175],"The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged \\>2 and \\\u003C18 years in two doses (64 mg or 48 mg every 4 weeks) depending on patient's weight. Secondary objectives are to evaluate the pharmacodynamic (PD) profile, the long-term efficacy and safety of olokizumab in patients with polyarticular juvenile idiopathic arthritis aged \\>2 and \\\u003C18 years.",[29],[303,304,305,306,307,308,309,310],"olokizumab","interleukin-6 (IL-6)","C-reactive protein (CRP)","Musculoskeletal Diseases","Autoimmune Diseases","Rheumatic Diseases Connective Tissue Diseases","Arthritis","Juvenile Arthritis","2026-04-01",{"date":313,"type":40},"2026-04-08",{"date":315,"type":40},"2023-03-17",{"date":317,"type":23},"2030-06",{"name":319,"class":47},"R-Pharm International, LLC",14,{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":18,"minAge":328,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":79},"100611684","regulatory-post-marketing-surveillance-in-hidradenitis-suppurativa-pediatric-plaque-psoriasis-and-jia-treated-with-cosentyxsecukinumab-in-korea-100611684","NCT07243782","Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea","Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study","Inclusion Criteria:\n\nHidradenitis suppurativa:\n\n1. Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.\n2. Patients who have agreed to participate in study (written informed consent)\n\nPediatric plaque psoriasis:\n\n1. Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.\n2. Patients with patient or guardian consent to participate in study (written informed consent)\n\nJuvenile idiopathic arthritis:\n\n1. Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.\n2. Patients with patient or guardian consent to participate in study (written informed consent)\n\nExclusion Criteria:\n\n1. Patients who are contraindicated according to national prescribing information\n2. Patients participating in other interventional clinical trials","6 Years","100 Years",{"count":331,"type":23},76,"Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea",[334,335,29],"Hidradenitis Suppurativa","Pediatric Plaque Psoriasis","2026-03-03",{"date":338,"type":40},"2026-03-05",{"date":340,"type":40},"2025-12-22",{"date":342,"type":23},"2027-06-15",{"name":344,"class":47},"Novartis Pharmaceuticals",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":87,"sex":18,"minAge":352,"maxAge":143,"enrollmentInfo":353,"targetDuration":4,"studyType":24,"phases":355,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":79},"100609684","pain-in-juvenile-arthritis-100609684","NCT07217782","Pain in Juvenile Arthritis","Pain Processing Mechanisms in Patients With Juvenile Arthritis","Inclusion Criteria:\n\n1. Age between 9-17\n2. Males and females\n3. English speakers\n4. Able to complete surveys and understand study instructions\n5. Juvenile arthritis group: diagnosed or suspected of juvenile arthritis\n6. Control group: healthy\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. (Control Group) Diagnosed with a chronic pain condition\n3. (Control Group) Diagnosed with psychiatric condition including ADHD, anxiety, depression, etc.","9 Years",{"count":354,"type":23},140,[62],"Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in children. The main symptoms of JIA, which are often the primary focus of treatment, include joint swelling, stiffness, and tenderness. Additional symptoms can include malaise, fatigue, and pain. However, the exact mechanisms contributing to pain are not yet fully understood. Participants will complete a 2.5-hours study session.\n\nIn the study session, psychophysical assessments of thermal and pressure stimuli will be performed. In addition, demographic, social, pubertal maturation, and behavioral and psychological factors will be collected via questionnaires. A saliva sample and\u002For blood draw may occur for the analysis of various immune factors and sex hormones. If a joint aspiration is done as part of their standard of care, we will request a sample of the synovial fluid for analyses of immune, hormonal and\u002For genetic factors. Participants will have the option to participate in additional optional follow-up study visits (every 3 months, up to 1 year) and to complete monthly surveys asking about their juvenile arthritis.",[29],"2025-10-14",{"date":360,"type":40},"2025-10-16",{"date":362,"type":40},"2025-09-15",{"date":364,"type":23},"2035-09",{"name":366,"class":78},"Washington University School of Medicine",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":374,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":401,"locationsCount":79},"100431799","conception-of-a-diagnosis-prognosis-and-therapeutic-decision-tool-for-patients-with-autoimmunity-and-inflammation-100431799","NCT04902807","Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation","ATRACTion","Inclusion Criteria for controls (patients relatives and unrelated subjects):\n\n* Individuals aged\\\u003C18 y\u002Fo.\n* Individuals \\> 6 kg\n* Individuals not affected by an immune-related disease or not affected by cancer\n* Individuals whose parents have signed an enlightened consent.\n\nInclusion criteria for patients\n\n* Individuals with health insurance.\n* Patients treated at Necker hospital with PIDs and autoimmunity\u002Finflammation related to known genetic defects (cytopenia, Enteropathy Inflammatory bowel disease (IBD), Systemic Lupus Erythematosus (SLE), Juvenile Idiopathic Arthritis (JIA), Familial Hemophagocytic Lymphohistiocytosis (FHL), chronic EBV infection associated (Ca-EBV) with EBV-infected T and\u002For Natural Killer (NK) cells and with a high risk to develop macrophage activation syndrome similar to FHL. See table below for diagnosis inclusion criteria.\n* Individuals aged\\\u003C18 y\u002Fo.\n* Individuals \\> 9 kg\n* Patients whose parents have signed an enlightened consent.\n\nExclusion Criteria:\n\n* Intake of antibiotics within 2 weeks prior inclusion\n* Absence of parent's or child consent form\n* Cytotoxic cancer treatments\n* antiviral treatments (HIV, hepatitis …)\n* Short term life-threatening conditions\n* Individuals placed under judicial protection",{"count":375,"type":23},500,"The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity\u002Finflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).",[378,379,307,380,381,382,383,384,278,29,385,386,387,388,389,390,391,392,393,394],"Autoimmune Lymphoproliferative Syndrome","Autoimmune Cytopenia","Autoimmune Anemia","Autoimmune Thrombocytopenia","Autoimmune Hepatitis","Autoimmune Diabetes","Autoimmune Rheumatologic Disease","Hemophagocytic Lymphohistiocytoses","EBV Lymphoproliferation","RAS-Associated Autoimmune Leucoproliferative Disease","Primary Immunodeficiency","APECED","IPEX","BENTA","Enteropathy, Autoimmune","Combined Immunodeficiency","IBD","2025-09-02",{"date":397,"type":40},"2025-09-08",{"date":399,"type":40},"2021-09-07",{"date":73,"type":23},{"name":402,"class":403},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":87,"sex":18,"minAge":4,"maxAge":89,"enrollmentInfo":410,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":4},"100599359","assessment-of-composite-inflammatory-ratios-in-juvenile-idiopathic-arthritis-and-their-association-with-disease-activity-100599359","NCT07083466","Assessment of Composite Inflammatory Ratios in Juvenile Idiopathic Arthritis and Their Association With Disease Activity","Inclusion Criteria:\n\n\\-\n\n1\\. Patients who classified JIA according to International League of Associations for Rheumatology ILAR criteria on treatment with exclusion of systemic JIA.\n\n2\\. Patients with disease duration more than 6 months. 3. Age below 16 years old. 4. Patient cooperative and can answer questions. 5. Patients who are able and willing to give written informed consent or their parents\u002Fguardians\n\nExclusion Criteria:\n\n* 1\\. Systemic JIA. 2. Patients with other autoimmune or autoinflammatory diseases, immunodeficiencies, hematologic conditions, malignances and infectious disease at enrollment time or in the previous 2 weeks.\n\nPatients who are not able and willing to give written informed consent",{"count":145,"type":23},"Juvenile Idiopathic Arthritis (JIA) is a prevalent pediatric rheumatic disorder characterized by persistent inflammation of one or more joints in children and adolescents. This chronic condition is a major contributor to both short- and long-term morbidity and functional disability We aim in this study to investigate the role of CAR, PLR, NLR ,systemic inflammatory index (SII ) and NAR ( SII and NAR have never been evaluated before in JIA patients ) as potential markers of disease activity in patients with non-systemic JIA (nsJIA) .",[29],"2025-07-16",{"date":415,"type":40},"2025-07-24",{"date":417,"type":23},"2025-07-15",{"date":419,"type":23},"2026-04-15",{"name":421,"class":78},"Sohag University",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":430,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":440,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":452},"100544996","m3-jia-making-mindfulness-matter-for-children-with-jia-100544996","NCT06376149","M3-JIA: Making Mindfulness Matter for Children With JIA","A Pilot Randomized-controlled Trial Evaluating the Efficacy of a Live-Online Mindfulness-Based Intervention: The Making Mindfulness Matter© in Children With Juvenile Idiopathic Arthritis Study","M3-JIA","Inclusion Criteria:\n\n* Children aged 4 to 12 years diagnosed with JIA\n* Children have reasonable comprehension of spoken language and can follow simple instructions\n* Children with JIA and their caregivers are willing to attend intervention sessions and have access to technology and internet to attend the online sessions.\n* Children with JIA and their caregivers have an adequate understanding of English\n\nExclusion Criteria:\n\n* Other major co-morbid disorders (e.g. Crohn's disease, diabetes, renal failure).\n* Concurrent enrollment in other intervention trials or practicing any complementary health interventions such as yoga, meditation, or daily mindfulness practice.","4 Years","12 Years",{"count":433,"type":23},74,[62],"The investigator will evaluate the efficacy of M3©, an intervention for patients with JIA and their caregivers. Children with Juvenile arthritis and their parents will attend an 8 week online program called Making Mindfulness Matter (M3). This is a facilitator-led program that integrates knowledge and skills related to mindfulness, social-emotional learning, neuroscience, and positive psychology to promote coping and resiliency for children and families in context of the challenges of pediatric chronic disease. The child program is designed for children 4-12 years of age, with each lesson including a variety of concrete ways to teach children skills based on their age\u002Fdevelopmental level.",[29,437,438,439],"Children","Mental Health","Mental Well-being",[441,442],"M3","mindfulness","2025-06-06",{"date":445,"type":40},"2025-06-11",{"date":447,"type":40},"2024-09-12",{"date":449,"type":23},"2026-02",{"name":451,"class":78},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",3,{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":296,"maxAge":460,"enrollmentInfo":461,"targetDuration":117,"studyType":92,"phases":4,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":79},"100593013","medical-follow-up-of-new-cases-of-polyarthritis-in-children-and-young-adults-100593013","NCT07000916","Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults. Optimization of Clinical Response, Remission, Quality of Life and Analysis of Prognostic Markers","Inclusion Criteria:\n\n* Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative \u002F psoriatic \u002F undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria).\n* Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.\n\nExclusion Criteria:\n\n* Treated for \\> 3 months\n* \\> 50 years old","50 Years",{"count":462,"type":23},1000,"Population:\n\nJuvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative \u002F psoriatic \u002F undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).\n\nNaïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.\n\nThese 5 cohorts will be subject to standardized clinical monitoring.",[29,465,466,278,467,468],"Rheumatoid Arthritis","Psoriatic Arthritis","Diffuse Systemic Sclerosis","Seronegative Arthritis","2025-05-22",{"date":471,"type":40},"2025-06-03",{"date":473,"type":40},"2013-09-11",{"date":475,"type":23},"2028-03-31",{"name":477,"class":78},"Université Catholique de Louvain",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":296,"maxAge":143,"enrollmentInfo":486,"targetDuration":4,"studyType":24,"phases":488,"briefSummary":490,"conditions":491,"keywords":492,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":237},"100566319","phase-4-optimizing-treatment-for-patients-with-juvenile-idiopathic-arthritis-in-sustained-remission-the-move-jia-trial-100566319","NCT06653634","Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial","Optimizing Treatment for Children and Adolescents With Juvenile Idiopathic Arthritis in Sustained Remission: a Comparison of Three Treatment Strategies. The MOVE-JIA Trial","MOVE-JIA","Inclusion Criteria:\n\n1. Participant must be 2-\\\u003C18 years of age at the time of signing the informed consent.\n2. Fulfilment of the International League of Associations for Rheumatology (ILAR) classification criteria for non-systemic Juvenile Idiopathic Arthritis (JIA).\n3. Inactive disease for ≥12 months documented at a minimum of 2 consecutive visits and documented inactive disease according to Wallace criteria at inclusion, and no active uveitis for ≥24 months.\n4. Stable treatment with methotrexate and Tumor Necrosis Factor inhibitor (TNFi) for ≥6 months. Weight adjustments permitted.\n5. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).\n6. Male participants: No contraceptive measures necessary.\n7. Female participants: contraception guidance for women of childbearing potential (WOCP).\n\nExclusion Criteria:\n\n1. Chronic widespread pain syndrome\n2. Major comorbidity including uncontrolled infectious, neurological or mental disease, malignant disease, severe heart failure, severe renal failure, active ulcus ventriculi, and uncontrolled diabetes mellitus.\n3. Use of oral, intra-articular, intramuscular or intravenous corticosteroids due to JIA less than 12 months prior to randomization.\n4. Participating in an ongoing clinical randomized study..\n5. Drug\u002Falcohol abuse which hampers adherence to the study protocol as based on the investigators judgement.\n6. Language barriers that hamper adherence to the study protocol.\n7. Pregnancy or breastfeeding.\n8. Any condition that in the view of the investigator would suggest that the patient is unable to comply with the study protocol and procedures.\n9. Unwillingness to use safe contraception for sexually active WOCP.",{"count":487,"type":23},150,[489],"PHASE4","The goal of this clinical trial is to compare three different maintenance and step-down treatment strategies in children and adolescents with juvenile idiopathic arthritis in sustained remission. The main questions it aims to answer are:\n\n* Is the proportion of study participants with a disease flare different between each of the two drug withdrawal arms and the stable treatment arm during 12 months?\n* Does the proportion of study participants with a disease flare differ between the two drug withdrawal arms during 12 months?\n* How long time does it take before a disease flare occurs, and how long does it take before disease remission is reestablished for participants in the different treatment arms?\n\nParticipants will be randomized to either A) continued stable treatment with methotrexate and tumor-necrosis alpha inhibitor (TNFi); B) gradual withdrawal of methotrexate while continued stable dose TNFi; or C) gradual withdrawal of TNFi.\n\nParticipants will be examined every 4 month, and with extra visits if they experience increased symptoms or suspect a disease flare. If a flare occurs, the medications received at study inclusion will be restarted.",[29],[254,493,494,495],"maintenance treatment","medication withdrawal","withdrawal","2025-03-19",{"date":498,"type":40},"2025-03-24",{"date":500,"type":40},"2024-10-24",{"date":502,"type":23},"2029-12",{"name":504,"class":78},"Oslo University Hospital",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":328,"maxAge":20,"enrollmentInfo":513,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":4},"100549264","prospective-observational-study-to-evaluate-secukinumab-treatment-effectiveness-in-pediatric-patients-with-active-juvenile-enthesitis-related-or-psoriatic-arthritis-100549264","NCT06431750","Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis","Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis (Toddler)","Toddler","Inclusion Criteria:\n\n1. Written informed consent and legal representative's permission for study participation obtained prior to beginning of participation in the study.\n2. Age ≥6 to \\\u003C18 years old.\n3. Recognized physician diagnosis of active ERA or jPsA:\n\n   * ERA per ILAR criteria:\n\n     * Peripheral arthritis and enthesitis, or\n     * Arthritis or enthesitis, plus ≥ 3 months of inflammatory back pain and sacroiliitis on imaging, or\n     * Arthritis or enthesitis plus 2 of the following: sacroiliac joint tenderness; inflammatory back pain; presence of HLA-B27 antigen; acute (symptomatic) anterior uveitis; and history of a spondyloarthritis in a first-degree relative.\n   * jPsA per ILAR criteria\n\n     * Arthritis and psoriasis, or\n     * arthritis and at least 2 of the following:\n\n       * Dactylitis\n       * Nail pitting or onycholysis\n       * Psoriasis in a first-degree relative.\n4. Patient was prescribed with secukinumab within 4-8 weeks before inclusion.\n5. Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of this non-interventional study conduct.\n6. The Purified Protein Derivative (PPD) Skin Test for Tuberculosis and\u002For Negative T-SPOT test and\u002For TB-feron test before secukinumab treatment and every 6 months.\n\nExclusion Criteria:\n\n1. Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex).\n2. Chronic recurrent infections.\n3. Clinically significant infection exacerbation, including active tuberculosis.\n4. Age \\\u003C6 years or ≥18 years.\n5. Pregnancy and breastfeeding.\n6. Patients participating in parallel in an interventional clinical trial.\n7. Patients participating in parallel in other Novartis-sponsored non-interventional study generating primary data for secukinumab.\n8. Patients within the safety follow-up phase of interventional study.\n9. Active inflammatory bowel disease at inclusion.\n10. Patients who received any vaccine within 4 weeks prior to secukinumab initiation.\n11. Any medical or psychological condition in the investigator's opinion which may prevent the study participation.\n12. Concomitant conditions (Candida infections, other infections, inflammatory bowel disease \\[IBD\\], uveitis, skin and nail psoriasis for ERA patients, hepatitis B, hepatitis C, tuberculosis).",{"count":487,"type":23},"This is a multicenter, non-interventional, cohort study in pediatric patients with active juvenile enthesitis-related or psoriatic arthritis",[29],[29,254,517,518],"Secukinumab","Cosentyx","2025-01-12",{"date":521,"type":40},"2025-01-14",{"date":523,"type":23},"2025-04-30",{"date":525,"type":23},"2028-08-30",{"name":344,"class":47},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":431,"maxAge":143,"enrollmentInfo":534,"targetDuration":4,"studyType":24,"phases":535,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":79},"100530232","virtual-self-management-program-for-jia-100530232","NCT06184100","Virtual Self-Management Program for JIA","Feasibility and Acceptability of a Virtual Self-management Program - A Pilot Randomized Controlled Trial for Adolescents With Juvenile Idiopathic Arthritis","Inclusion Criteria:\n\n1. Adolescents between the ages of 12 and 17\n2. Confirmed diagnosis within 2 years according to the International League of Associations for Rheumatology JIA classification criteria (2)\n3. Followed in one of the pediatric rheumatology clinics participating in the RCT\n4. Able to access the Internet on a computer\n5. Willing and able to complete online measures\n\nExclusion Criteria:\n\n1. Insufficient English reading and speaking skills\n2. Untreated psychiatric or comorbid disorders or major cognitive impairments leading to inability to understand materials and participate in the SMP group activities.\n3. Other chronic conditions such as other autoimmune disease, neurologic, orthopedics or other systems disorder (e.g. heart, kidney) that might influence outcome assessments\n4. Past participation in the last year or participating in another peer-support or self-management program",{"count":119,"type":23},[62],"The aim of this project is to conduct a pilot randomized controlled trial (RCT) to evaluate the feasibility and preliminary effectiveness of a virtual group based self-management program (SMP) in adolescents with JIA across different provinces compared to a wait-list control group receiving only standard of care.\n\nParticipants in the SMP group will partake in four 60-90 minute group sessions conducted over 8 weeks. The intervention is a multifaceted program that includes JIA disease education, self-management strategies, and peer support. Both the interventional and control group will be asked to complete baseline and post-test measures.\n\nParticipants in the control group will be offered the SMP after completion of the post-control outcome measures.",[29],[539,540,541,254,542],"Virtual","Education","Clinical Trial","Self-management Program","2024-12-04",{"date":545,"type":40},"2024-12-09",{"date":547,"type":40},"2023-12-13",{"date":549,"type":23},"2026-03",{"name":551,"class":78},"University of Calgary",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":20,"enrollmentInfo":559,"targetDuration":296,"studyType":92,"phases":4,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":571},"100559167","ucan-can-du-canada-netherlands-personalized-medicine-network-in-childhood-arthritis-and-rheumatic-disease-100559167","NCT06560606","UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease","UCAN CAN-DU","Inclusion Criteria:\n\nCohort 1: - Biologic Basis of JIA\n\n* ≤18 years\\*\n* Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment\n* Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis\n\nCohort 2 - Start Biologics\n\n* JIA diagnosis as per ILAR criteria (all subtypes)\n* ≤18 years\\*\n* Active arthritis\n* For sJIA, active disease not necessarily with arthritis.\n* Time of start, restart or switch biologic therapy: e.g. failure, insufficient\u002Fpartial response or intolerance\n\nCohort 3 - Stop Biologics\n\n* JIA diagnosis as per ILAR criteria (all subtypes)\n* ≤18 years\\*\n* Inactive disease\n* Discontinuing\u002Ftapering biologics for inactive disease\n\nCohort 4: Extreme Phenotypes\n\n* Unexplained systemic inflammation with arthritis\u002Farthralgia as a part of manifestations\n* High suspicion of genetic contribution\n* Severely affected patients with difficult to control disease (ie failure of multiple biologics)\n\nExclusion Criteria:\n\nCohort 1 :\n\n* Arthritis explained by another diagnosis\n* Joint injections as previous treatment less than 4 weeks prior to enrollment\n\nCohort 2:\n\n* Arthritis explained by any other cause\n* Start on biologics as an indication for uveitis only\n\nCohort 3:\n\n\\- Tapering scheme \\> 12 months to complete biologics stop\n\nCohort 4:\n\n\\- Arthritis explained by another diagnosis",{"count":560,"type":23},4100,"Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.",[29],"2024-08-16",{"date":565,"type":40},"2024-08-19",{"date":567,"type":40},"2018-08-24",{"date":569,"type":23},"2027-03-30",{"name":236,"class":78},19,{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":20,"enrollmentInfo":579,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":580,"conditions":581,"keywords":582,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":594},"100516663","clinical-laboratory-and-ultrasound-stratification-of-patients-with-juvenile-idiopathic-arthritis-100516663","NCT06007456","Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis","Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis and Outcomes Evaluation During Transition to Adult Care","Inclusion Criteria:\n\n* Subjects under the age of 18 years\n* Arthritis persisting for at least 6 weeks with no known cause\n\nExclusion Criteria:\n\n* No consent from the patients' guardians\n* Patients with Systemic onset Juvenile Idiopathic Arthritis\n* Patients who developed arthritis on a pre-existing inflammatory disorder such as Inflammatory Bowel Disease, and had received previous treatments",{"count":48,"type":23},"Juvenile Idiopathic Arthritis (JIA), the most common rheumatologic chronic disease in children, is defined as arthritis persisting for at least 6 weeks with no known cause in a patient under the age of 16. The term JIA is an umbrella that includes very different diseases. The current International League of Associations for Rheumatology (ILAR) classification divides JIA patients into 7 categories based on number of involved joints and time of involvement, presence of systemic symptoms, psoriatic findings and spondyloarthritis. This classification groups together patients with different disease and divides patients with the same disease. In the first case, unifying distinct diseases could lead to undifferentiated therapeutic choices, moving away from the modern concept of therapeutic personalization. In the second case, similarities between paediatric and adult arthritis could not be found. This involves both a loss of collaboration with the adult rheumatologist and the difficulty in accessing possibly effective therapies approved only for adult arthritis.\n\nIn clinical practice, it is increasingly evident that the number of affected joints and the speed of joint involvement are not useful criteria for defining the type and severity of disease. Joint counts lead to underestimate the importance of joint distribution in the identification of distinct forms of arthritis. A recent study found that patterns of joint involvement represent prognostic features, so grouping patients by joint pattern and degree of localization may help clinicians tailor treatments based on predicted disease trajectories. Another important point to differentiate some forms of arthritis is the presence of enthesitis and tenosynovitis. Sometimes tendon inflammation can be not clinically evident, so ultrasound evaluation is useful to detect it. Musculoskeletal ultrasound (MSUS) has been used worldwide by adult rheumatologist, but it is beginning a useful tool also in patients with JIA. Recent studies underline the important role of MSUS findings to assess disease activity and assist disease classification. In recent years, the need has emerged to replace the ILAR criteria with a new nomenclature based on the disease biology. This approach could help clinicians to choose a personalized therapeutic strategy for patients with arthritis.",[29],[254,583,584],"classification","transition of care","2024-06-13",{"date":587,"type":40},"2024-06-14",{"date":589,"type":40},"2022-01-10",{"date":591,"type":23},"2026-03-15",{"name":593,"class":78},"IRCCS Burlo Garofolo",2,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":87,"sex":18,"minAge":601,"maxAge":89,"enrollmentInfo":602,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":4},"100547868","analysis-of-peripheral-blood-lymphocytes-in-patients-with-juvenile-idiopathic-arthritis-with-respect-to-disease-subtypes-and-therapy-100547868","NCT06413563","Analysis of Peripheral Blood Lymphocytes in Patients With Juvenile Idiopathic Arthritis With Respect to Disease Subtypes and Therapy","Inclusion Criteria:\n\n* 1\\. Patient age is above 16 years old 2. Patients who classified JIA according to International League of Associations for Rheumatology ILAR criteria received DMARDS therapy and in inactive state of disease\n\nExclusion Criteria:\n\n* 1\\. Patients with active JIA 2. Any patient with any autoimmune disease other than JIA 3. Acquired and congenital lymphopenia","6 Months",{"count":603,"type":23},75,"Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children.\n\nJIA is an umbrella term defining several forms of chronic arthritis with an onset before the age of 16 years, persisting for more than six weeks and with an unknown cause.\n\nBased on the current International League of Associations in Rheumatology classification criteria (ILAR 2003) , different subtypes of JIA can be distinguished, essentially by a very limited set of clinical features (number of affected joints in the first six months of disease, extra-articular manifestations like fever or features of psoriasis) and serology (presence or absence of rheumatoid factor, RF). The most frequently diagnosed JIA subtypes are oligoarticular JIA (oJIA), polyarticular JIA (pJIA), and systemic JIA (sJIA). Less frequently occurring subtypes are enthesitis-related JIA, psoriatic arthritis, and undefined arthritis.\n\nThe pathophysiology mechanisms associated to JIA development are related to an abnormal activation of immune system cells such as B cells, T cells, natural killer (NK) cells, dendritic cells (DCs), monocytes, neutrophils, plasma cells, and to the production and release of pro-inflammatory mediators that ultimately lead to cartilage and bone destruction and systemic manifestations.\n\nJIA has been classically considered a T-cell driven autoimmune disease, except for sJIA subtype, in which innate immune cells have a central role in disease pathogenesis. However, the detection of autoantibodies reacting with different target antigens in JIA patients suggests a central role of B cells in JIA pathophysiology.\n\nTherapeutic intervention of jia begins at diagnosis with non-steroidal anti-inflammatory drugs (NSAIDs) followed by disease-modifying anti-rheumatic drugs (DMARDs, most often methotrexate) and\u002For corticosteroid intra-articular injection.\n\nNSAIDs obtain both analgesic and anti-inflammatory effects. Local corticosteroid joint injections are effective in synovitis and may be a first-line treatment for oligoarthritis alone or in addition to DMARDs. Systemic administration of high dose corticosteroids provides good short-term effect, especially in sJIA patients.\n\nThe American College of Rheumatology (ACR) recommends early use of DMARDs, specifically MTX, leflunomide and\u002For sulfasalazine.\n\nMTX is considered to be the first choice DMARD for oligo- and pJIA when NSAIDs and intraarticular steroids are insufficient.\n\nMTX is also considered to be effective in children with PsJIA, though the axial manifestations limits prescription of MTX and so TNF inhibitors are typically required in these cases.\n\nLeflunomide may be used as an alternative DMARD for pJIA in cases of MTX intolerance.\n\nSulfasalazine is recommended for patients with moderate activity of ERA with active peripheral arthritis, but is inefficient in case of sacroiliitis.\n\nThe emergence of biologic treatments has changed the prognosis for many JIA patients, whose condition did not improve adequately on conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), mainly methotrexate, or experienced side effects because of them. TNF-α inhibitors, such as etanercept, adalimumab , infliximab are widely used in JIA. In fact, etanercept is one of the most frequently prescribed biologics for JIA in many countries, including the United Kingdom. (19) Other biologics include tocilizumab , anakinra and canakinumab , abatacept and rituximab . The efficacy of biologics varies depending on the disease subtype.\n\nMost healthy children have episodes of mild infections during the first years of life. In most cases, these episodes are respiratory or gastrointestinal viral infections. Children with juvenile idiopathic arthritis (JIA) have an allegedly higher risk of infection compared with healthy children because of their underlying condition.\n\nTreatments used in JIA include corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents, all of which can increase the frequency of common mild infections and the risk of severe and opportunistic infections.\n\nDisease-modifying anti-rheumatic drugs (DMARDs) help manage JIA by reducing inflammation and preventing joint damage, slowing the progression of the disease.\n\nThese therapies work by suppressing the immune system, which can lead to infection, despite growing evidence regarding the efficacy and safety of these drugs for children with JIA, it is unclear whether these agents increase the risk of infections - or whether the risk is increased to all or to only specific infections.\n\nMoreover, there is a proportional relationship between the severity of the disease and the intensity of the treatment administered, and this association might constitute a confounding factor when assessing susceptibility to infections.\n\nBesides novel findings, there is still little data available regarding the alteration of immune cells which control infection.",[29],"2024-05-09",{"date":608,"type":40},"2024-05-14",{"date":610,"type":23},"2024-07-15",{"date":612,"type":23},"2026-11-30",{"name":421,"class":78},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":18,"minAge":296,"maxAge":431,"enrollmentInfo":622,"targetDuration":4,"studyType":24,"phases":623,"briefSummary":624,"conditions":625,"keywords":627,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":79},"100514919","imaging-based-uveitis-screening-for-children-with-juvenile-idiopathic-arthritis-100514919","NCT05984758","Imaging Based Uveitis Screening for Children With Juvenile Idiopathic Arthritis","A Randomised Feasibility Study of Imaging Based Uveitis Screening for Children With Juvenile Idiopathic Arthritis","UVESCREEN1","Inclusion Criteria:\n\n* Patients newly diagnosed (within preceding 12 months) with JIA who are eligible for uveitis surveillance\n* Aged 2-12 years\n\nExclusion Criteria:\n\n* A previous \u002F existing diagnosis of uveitis\n* Any co-existing ocular or neurological abnormality which impacts on current corrected visual function, or could impact on future corrected visual function\n* Developmental\u002Flearning difficulties that preclude concordance with examination \u002F informed assent",{"count":48,"type":23},[62],"This study seeks to describe, for children undergoing uveitis surveillance following a new diagnosis of juvenile idiopathic arthritis, the feasibility metrics of undertaking a randomised comparative study of routine slit lamp examination (SLE) versus imaging based (anterior segment optical coherence tomography, OCT) surveillance in order to inform the development of a larger multi-centre trial.",[626,29],"Uveitis, Anterior",[628,629,630,631],"Screening","Surveillance","Imaging","Optical coherence tomography","2024-03-11",{"date":634,"type":40},"2024-03-12",{"date":636,"type":23},"2024-05-01",{"date":638,"type":23},"2026-10-01",{"name":640,"class":78},"Institute of Child Health",{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":647,"eligibilityCriteria":648,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":649,"targetDuration":4,"studyType":24,"phases":651,"briefSummary":652,"conditions":653,"keywords":654,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":79},"100463138","personalized-estimates-of-response-and-severity-outcomes-in-newly-diagnosed-jia-100463138","NCT05310799","Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed JIA","Treating Children With Arthritis According to Their Individual Probability of Outcomes and Response to Treatments","PERSON-JIA","Physicians (Inclusion):\n\n1. Licensed to practice pediatric rheumatology in Canada;\n2. Providing care for children with JIA at least once a month;\n3. Consent to be randomized and to implement the SDM intervention for the duration of the trial, if randomized to the intervention arm;\n4. Commit to propose enrollment in the Registry to all their newly diagnosed patients with JIA during the trial.\n\nPhysicians (Exclusion):\n\n1. Fellows-in-training;\n2. Physicians planning to retire within 2 years.\n\nPatient (Inclusion):\n\n1. Consent to include their information in the CAPRI JIA Registry;\n2. Consent to the PERSON-JIA trial and answering additional questionnaires to assess decision making;\n3. Allow recording of their medical encounter (if selected at random);\n4. JIA fulfilling International League of Associations for Rheumatology (ILAR) criteria;\n5. Newly diagnosed (within the last month);\n6. Diagnosed by a pediatric rheumatologist participating in the PERSON-JIA study;\n7. Not yet receiving treatment, or received only Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) or joint injections;\n\nPatient (Exclusion):\n\n1. Systemic arthritis category of JIA (it requires a different treatment approach);\n2. Family is unable to complete study forms in English or French;\n3. Patients who have already started systemic corticosteroid or any Disease Modifying Anti-Rheumatic Drug (DMARD).",{"count":650,"type":23},842,[62],"The PERSON-JIA Trial is a cluster-randomized trial testing the use of Shared Decision Making (SDM) with families for treatment of children with arthritis. The intervention is a discussion between physicians and families at the time of diagnosis that uses computer-generated personalized outcome reports generated by previously developed prediction algorithms.\n\nBy using information provided by thousands of families, the investigators have developed a way of providing answers to common questions asked by patients and their families at diagnosis.\n\nWe will test whether a structured discussion and shared decision between families and doctors (guided by the patient's personal report) will improve the tailoring of treatment to the child and control of their disease. The personal report is called the PERSON-JIA report and presents the child's expected disease severity, the likelihood the child will be arthritis free by age 18 and the chance treatments will be effective and\u002For have side effects. This way, answers to these questions can be shared by physicians and families to weigh potential benefits and harms according to family values and preferences.\n\nThe investigators expect that using the personalized report in a frank and thoughtful discussion will help physicians and families make better decisions about managing the child's disease. This in turn will result in better disease control, greater family engagement and satisfaction with care and better-tailored treatment. If so, this will be a ground-breaking way of using information provided by families and doctors to improve the care provided to and the outcomes of children with arthritis in Canada.",[29],[66,222,309,655,656,657,647,658],"Shared decision making","Clinical outcomes","Canada","PERSON JIA","2023-11-29",{"date":661,"type":40},"2023-12-06",{"date":663,"type":40},"2023-05-23",{"date":665,"type":23},"2029-02",{"name":667,"class":78},"University of British Columbia"]